Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Vasileios Pardalis"'
Autor:
Maria Dimou, Aikaterini Bitsani, Maria Roumelioti, Aglaia Dimitrakopoulou, Theodore Iliakis, Vasileios Pardalis, Ioannis Grafakos, Sotiria Kalyva, Athanasios Markopoulos, Marie‐Christine Kyrtsonis, Panayiotis Panayiotidis
Publikováno v:
Clinical Case Reports, Vol 9, Iss 4, Pp 2249-2253 (2021)
Abstract Our unique case of Richter's Transformation presenting as leptomeningial infiltration in a CLL patient receiving venetoclax raises questions on whether the drug penetrates the blood‐brain barrier and at what extend, especially in reduced d
Externí odkaz:
https://doaj.org/article/bd5d28430ca74e60a6e31c467814826e
Autor:
Aspasia Koudouna, Aikaterini Bitsani, Theodoros Iliakis, Vasiliki Bartzi, Maria Dimou, Annita Ioanna Gkioka, Panayiotis Panayiotidis, Mavra Papadatou, Vasileios Pardalis, Alexandros Gkiokas, Marie-Christine Kyrtsonis
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S85-S86
Background Lenalidomide refractoriness constitutes an adverse factor of survival in MM as Lenalidomide relapsing/resistant patients were reported to respond difficultly to next treatment line. Lenalidomide is widely administered in doublet, triplet,
Autor:
Theodoros Iliakis, Panayiotis Panayiotidis, Marie-Christine Kyrtsonis, Aikaterini Bitsani, Maria Dimou, Vasileios Pardalis
A 51-year male patient presented with large skin masses of the chest wall that were pathologically proven to be chronic lymphocytic leukemia/small lymphocytic lymphoma(CLL/SLL) with Ki67:70%. The patient was treated with the time-limited Venetoclax/O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6fc614099192a5f02af573d920ce41e9
https://doi.org/10.22541/au.161086592.29938502/v1
https://doi.org/10.22541/au.161086592.29938502/v1
Autor:
Panayiotis Tsaftaridis, Theodoros P. Vassilakopoulos, Maria Dimou, Aspasia Koudouna, Theodoros Iliakis, Vasileios Pardalis, Panayiotis Panayiotidis, Sotiria Kalyva, Paraskevi Papaioannou, Marie-Christine Kyrtsonis, Maria K. Angelopoulou, Catherin Bitsani
Publikováno v:
Leukemialymphoma. 60(12)
Ibrutinib (IB) revealed high efficacy and safety profile in phase 2/3 chronic lymphocytic clinical trials. Emerging real-world-data shows similar response and survival, but higher discontinuation rates due to adverse events (AEs). We present retrospe
Autor:
Marie-Christine Kyrtsonis, Vasileios Pardalis, Theodoros Iliakis, Maria Dimou, Athanasios Markopoulos, Ioannis Anagnostopoulos, Sotiria Kalyva, Panayiotis Panayiotidis, Aikaterini Bitsasni
Publikováno v:
Blood. 136:1-1
Introduction Venetoclax, a novel BCL2 inhibitor, used either as monotherapy or in combinations, induces rapid disease control , with durable clinical remissions, especially in patients with deep responses. In the Venetoclax era, minimal residual dise
Autor:
Aikaterini Bitsani, Vasileios Pardalis, Theodoros Iliakis, Panayiotis Panayiotidis, Ioannis Grafakos, Athanasios Markopoulos, Marie-Christine Kyrtsonis, Sotiria Kalyva, Maria Dimou
Publikováno v:
Blood. 134:3429-3429
Intoduction Hematological malignancies are often complicated by secondary immunodeficiency (SID), namely hypogammaglobulinemia, the cause of common and opportunistic infections, which represent the major morbidity aitiology for hematological patients
Autor:
Niki Rougkala, Annita Ioanna Gkioka, Aspasia Koudouna, Theodoros Iliakis, Thomais Tryfou, Maria Dimou, Marie-Christine Kyrtsonis, Paraskevi Papaioannou, Ioannis Grafakos, Aikaterini Bitsani, Panayiotis Panayiotidis, Vasileios Pardalis, Panagiotis Repousis
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e117